Premium
Pharmacokinetics of diacerein in patients with liver cirrhosis
Author(s) -
Magnard O.,
Louchahi K.,
Tod M.,
Petitjean O.,
Molinier P.,
Berdah L.,
Perret G.
Publication year - 1993
Publication title -
biopharmaceutics and drug disposition
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.419
H-Index - 58
eISSN - 1099-081X
pISSN - 0142-2782
DOI - 10.1002/bdd.2510140506
Subject(s) - cirrhosis , pharmacokinetics , cmax , medicine , gastroenterology
The pharmacokinetics of diacerein following a single oral dose of 50 mg was studied in 12 healthy volunteers, 10 patients with a mild liver cirrhosis (Child Pugh's grade A), and 6 patients with a more severe liver cirrhosis (Child Pugh's grade B to C). Statistical analysis using a Kruskal‐ Wallis test showed no significant differences between the three groups for the following parameters: median C max was 3.9 mg l −1 for the cirrhotic patients group I (CPI) and 3.2 mg l −1 for the cirrhotic patients group II (CPII) versus 3.2 mg l −1 for the healthy volunteers (HV); median t 1/2 was 4.9 h for CPI and 4.3 h for CPII versus 4.3 h for HV; median Cl/ F was 2.1 l h −1 for CPI and 2.5 l h −1 for CPII versus 1.6 l h −1 for HV; median Vdss/ F was 12.6 l for CPI and 14.01 for CPII versus 13.2 l for HV. The urinary parameters were comparable. It was concluded that, from a pharmacokinetic point of view, no reduction in the initial dosage of diacerein need be proposed in liver cirrhosis.